TY - JOUR
T1 - Continuous hyperthermic peritoneal perfusion with cisplatin in mice with peritoneal dissemination of B16 melanoma
AU - Okuyama, Toshiro
AU - Endo, Kazuya
AU - Maehara, Yoshihiko
AU - Baba, Hideo
AU - Oshiro, Tatsuo
AU - Adachi, Yosuke
AU - Sugimachi, Keizo
PY - 1994
Y1 - 1994
N2 - We designed a model of peritoneal dissemination of gastric cancer in mice. B16 melanoma cells were injected into the peritoneal cavity of C57 BL mice, the object being to search for an effective treatment for peritoneal dissemination, using hyperthermia combined with cisplatin. Following the intraperitoneal administration of tumor cells, each mouse was subjected to continuous hyperthermic peritoneal perfusion (CHPP) using the peritoneal cavity expander (PCE), with or without cisplatin in the perfusate under conditions of laparotomy. Effects of the therapy were evaluated, based on comparison of survival time between the control and treated groups. There was no prolongation of mean survival periods for the groups given CHPP, with or without cisplatin, compared to findings in the no treatment control group. Optimal timing and doses of hyperthermia and cisplatin, or adding biochemical modulators to enhance the effects of cisplatin, will need to be determined to increase the efficacy of CHPP, with or without the concomitant administration of cisplatin. © 1994 Wiley‐Liss, Inc.
AB - We designed a model of peritoneal dissemination of gastric cancer in mice. B16 melanoma cells were injected into the peritoneal cavity of C57 BL mice, the object being to search for an effective treatment for peritoneal dissemination, using hyperthermia combined with cisplatin. Following the intraperitoneal administration of tumor cells, each mouse was subjected to continuous hyperthermic peritoneal perfusion (CHPP) using the peritoneal cavity expander (PCE), with or without cisplatin in the perfusate under conditions of laparotomy. Effects of the therapy were evaluated, based on comparison of survival time between the control and treated groups. There was no prolongation of mean survival periods for the groups given CHPP, with or without cisplatin, compared to findings in the no treatment control group. Optimal timing and doses of hyperthermia and cisplatin, or adding biochemical modulators to enhance the effects of cisplatin, will need to be determined to increase the efficacy of CHPP, with or without the concomitant administration of cisplatin. © 1994 Wiley‐Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0028359430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028359430&partnerID=8YFLogxK
U2 - 10.1002/ssu.2980100217
DO - 10.1002/ssu.2980100217
M3 - Article
C2 - 8052785
AN - SCOPUS:0028359430
SN - 8756-0437
VL - 10
SP - 145
EP - 149
JO - Seminars in Surgical Oncology
JF - Seminars in Surgical Oncology
IS - 2
ER -